GlassScriptPhysician profile
Manish B Bhuva
NPI 1518953330
$6,444.71
in general payments reported to CMS, 2019-2025
35 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $183 · 2021: $79.77 · 2022: $312 · 2023: $888 · 2024: $1,098 · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941 · Debt Forgiveness: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,940.54 |
| Debt Forgiveness | $977.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.03 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Olympus America INC. | $977.82 | 2025 | Evis Exera III Colonovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $511.31 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $355.07 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Madrigal Pharmaceuticals | $318.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $258.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.66 | 2019-2025 | Xifaxan, Plenvu |
| Ipsen Biopharmaceuticals, INC | $209.57 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $201.76 | 2022-2025 | |
| Pfizer INC. | $194.18 | 2019-2025 | |
| Celgene Corporation | $189.55 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $182.24 | 2019-2024 | Dificid |
| Ardelyx, INC. | $166.81 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $140.35 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $125.99 | 2019-2025 | Rebyota |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $123.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $120.81 | 2024-2025 | Voquezna |
| Vivus LLC | $107.63 | 2024-2025 | Pancreaze |
| Mauna Kea Technologies, INC. | $92.18 | 2019 | |
| Intercept Pharmaceuticals, INC. | $79.02 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $74.05 | 2019-2023 | Sucraid |
| Braintree Laboratories, INC. | $64.04 | 2020-2025 | Sutab, Suflave |
| Biocon Biologics INC | $47.57 | 2023-2025 | Yesintek, Hulio |
| Medtronic, INC. | $47.35 | 2024 | Gi Genius |
| Ironwood Pharmaceuticals, INC | $45.86 | 2019-2024 | Linzess |
| Celltrion USA INC. | $43.16 | 2025 | Vegzelma |
| Allergan, INC. | $38.75 | 2019 | |
| Evoke Pharma, INC. | $37.12 | 2022-2024 | |
| Ucb, INC. | $30.19 | 2019 | |
| Concordia Pharmaceuticals INC. | $30.06 | 2019 | |
| Aimmune Therapeutics, INC. | $26.01 | 2025 | Zenpep |
| Mirum Pharmaceuticals, INC. | $24.49 | 2025 | Livmarli |
| Capsovision, INC. | $23.08 | 2024 | Capsocam Plus |
| Lilly USA, LLC | $19.29 | 2025 | Omvoh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Bhuva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.